<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451815</url>
  </required_header>
  <id_info>
    <org_study_id>204-PD-201</org_study_id>
    <nct_id>NCT00451815</nct_id>
  </id_info>
  <brief_title>BIIB014 Phase 2a Monotherapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      To assess the preliminary safety and tolerability of multiple oral doses of BIIB014 in&#xD;
      subjects with early PD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Unless otherwise specified, to be eligible to participate in this study, candidates must&#xD;
        meet the following eligibility criteria at the time of the Baseline Visit (Day -1):&#xD;
&#xD;
          1. Must give written informed consent. Must also provide all authorizations required by&#xD;
             local law.&#xD;
&#xD;
          2. Aged 30 to 78 years old at the time of informed consent.&#xD;
&#xD;
          3. If female, must be postmenopausal for at least 1 year, surgically sterile, or willing&#xD;
             to practice effective contraception during the study. Nursing mothers, pregnant women,&#xD;
             and women planning to become pregnant while on study are to be excluded.&#xD;
&#xD;
          4. Carry a diagnosis of probable idiopathic PD, made by a Movement Disorder Specialist,&#xD;
             with asymmetric onset and at least 2 of the following cardinal features of PD:&#xD;
             bradykinesia, rigidity, or a classic PD resting tremor.&#xD;
&#xD;
          5. Be Hoehn &amp; Yahr Stage I-III inclusive when OFF.&#xD;
&#xD;
          6. Have a Total Unified PD Rating Scale (UPDRS) OFF score of Â³ 8.&#xD;
&#xD;
          7. Have taken no prescribed medications for PD for a minimum of 2 weeks before the&#xD;
             Baseline Visit (Day -1).&#xD;
&#xD;
          8. Are willing to abstain from alcohol for the duration of the study.&#xD;
&#xD;
          9. Have no clinically significant baseline ECG (12-lead) and laboratory abnormalities (as&#xD;
             determined by the Investigator), unless exempted by the Biogen Idec Medical Director.&#xD;
&#xD;
         10. Agree to provide blood samples for mRNA and DNA analysis, which will be collected and&#xD;
             banked and may be used for exploratory pharmacogenomic studies.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Unless otherwise specified, candidates will be excluded from study entry if any of the&#xD;
        following exclusion criteria exist at the time of the Baseline Visit (Day -1):&#xD;
&#xD;
          1. Mini Mental State Examination (MMSE) score &lt;27.&#xD;
&#xD;
          2. History or clinical features such as impaired downward gaze, prominent axial rigidity,&#xD;
             gait initiation failure, autonomic dysfunction, etc. consistent with an atypical&#xD;
             parkinsonism syndrome.&#xD;
&#xD;
          3. Any significant non-PD central nervous system disorder.&#xD;
&#xD;
          4. Significant AXIS I psychiatric disease as defined by Diagnostic and Statistical Manual&#xD;
             of Mental Disorders, 4th edition-Revised (DSM IV-TR, American Psychiatric Association,&#xD;
             2000).&#xD;
&#xD;
          5. History of surgical intervention for PD (pallidotomy, thalamotomy, deep brain&#xD;
             stimulation, etc.).&#xD;
&#xD;
          6. Participation in a previous adenosine A2A trial.&#xD;
&#xD;
          7. Participation in any other investigational drug study within 1 month prior to&#xD;
             randomization into this trial.&#xD;
&#xD;
          8. History of malignancy unless an exemption has been granted by the Biogen Idec Medical&#xD;
             Director.&#xD;
&#xD;
          9. History of severe allergic or anaphylactic reactions to a drug.&#xD;
&#xD;
         10. Clinically significant cardiac, renal, pulmonary, hematopoietic, endocrine, or hepatic&#xD;
             disease.&#xD;
&#xD;
         11. Abnormal laboratory results as follows: AST, ALT, total bilirubin, GGT levels &gt; 1.5 x&#xD;
             upper limit of normal; serum lipase &gt; upper limit of normal; WBC &lt; 4,000 cells/mm3&#xD;
             hemoglobin &lt; 10, or any other abnormal laboratory value that could interfere with the&#xD;
             assessment of safety.&#xD;
&#xD;
         12. Supine (measured in duplicate 10 minutes after resting) or standing (measured in&#xD;
             duplicate 3 minutes after changing from a supine to a standing position) blood&#xD;
             pressure of &gt;150 or &lt;90 mmHg systolic or &gt;90 or &lt;40 mmHg diastolic on 2 consecutive&#xD;
             occasions.&#xD;
&#xD;
         13. Orthostatic hypotension as defined by a decrease in systolic BP of &gt;20 mmHg or in&#xD;
             diastolic blood pressure of &gt; 10 mmHg measured in duplicate 3 minutes after changing&#xD;
             from a supine to standing position.&#xD;
&#xD;
         14. History of human immunodeficiency virus (HIV).&#xD;
&#xD;
         15. Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen&#xD;
             (HBsAg) at screening.&#xD;
&#xD;
         16. History of drug or alcohol abuse as defined by the DSM IV-TR (American Psychiatric&#xD;
             Association, 2000) within 1 year prior to randomization into this trial.&#xD;
&#xD;
         17. Alcohol use within 72 hours of Baseline Visit (Day -1).&#xD;
&#xD;
         18. Donation of blood or plasma in excess of 500 mL within 3 months of the Screening&#xD;
             Visit.&#xD;
&#xD;
         19. Unwillingness or inability to comply with the requirements of the protocol including&#xD;
             the presence of any condition (physical, mental, or social) that is likely to affect&#xD;
             the subject's ability to comply with the protocol.&#xD;
&#xD;
         20. Any other reasons that, in the opinion of the Investigator and/or the Sponsor, the&#xD;
             subject is determined to be unsuitable for enrollment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen Idec</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2007</study_first_posted>
  <last_update_submitted>March 23, 2007</last_update_submitted>
  <last_update_submitted_qc>March 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

